Semaglutide Explained: How It Works and Its Potential Benefits
Share
Semaglutide has become one of the most widely discussed compounds in modern metabolic research and clinical medicine. Originally developed to support the management of type 2 diabetes, it is now also used in licensed medicines for weight management and, in selected patients, the reduction of cardiovascular risk.
Its growing profile is connected to the way semaglutide influences appetite, blood-glucose regulation, insulin signalling and energy intake. However, semaglutide is not simply a cosmetic weight-loss shortcut.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 receptor agonist, commonly shortened to GLP-1 receptor agonist or GLP-1RA.
GLP-1 is a naturally occurring hormone released by the body after eating. It contributes to appetite regulation, insulin release, blood-glucose control and the speed at which food leaves the stomach.
Semaglutide is designed to mimic some of the biological activity of natural GLP-1 while remaining active in the body for longer. Depending on the licensed product and medical indication, semaglutide may be supplied as a weekly injection or an oral tablet.
How Does Semaglutide Work?
Semaglutide binds to and activates GLP-1 receptors found in several areas of the body.
Its principal effects include influencing appetite centres in the brain, increasing feelings of fullness, supporting glucose-dependent insulin release and reducing inappropriate glucagon activity when blood glucose is elevated.
Semaglutide can also slow gastric emptying. This means food may leave the stomach more slowly, contributing to prolonged fullness after meals. The same effect is one reason healthcare teams need to know about semaglutide use before an operation involving general anaesthesia or deep sedation.
Potential Benefits of Semaglutide
1. Reduced Hunger and Improved Appetite Control
One of semaglutide’s most recognised effects is its influence on hunger and satiety.
By activating GLP-1 receptors associated with appetite regulation, semaglutide may help people feel satisfied after consuming less food. Some patients also report fewer food cravings and less persistent preoccupation with eating.
This does not mean that semaglutide physically prevents someone from eating. Instead, it may make adherence to an appropriate reduced-calorie diet more manageable by reducing hunger and helping fullness last longer.
2. Clinically Significant Weight Loss
Semaglutide has produced meaningful weight reduction in clinical trials involving adults with obesity or overweight accompanied by qualifying health conditions.
In the STEP 1 trial, adults without diabetes received once-weekly semaglutide or placebo alongside lifestyle intervention. After 68 weeks, the semaglutide group experienced an average body-weight reduction of approximately 14.9%, compared with a much smaller change in the placebo group. Around 86% of participants receiving semaglutide lost at least 5% of their starting weight.
Individual results vary considerably. Some people lose more weight, while others experience a smaller response or stop treatment because of adverse effects.
Semaglutide is therefore best understood as a treatment that may support weight management when combined with nutrition, physical activity and ongoing clinical assessment—not as a replacement for these factors.
3. Better Blood-Glucose Regulation
Semaglutide was first established as a treatment for type 2 diabetes because of its effects on glucose control.
When blood glucose is elevated, semaglutide can support insulin secretion and reduce glucagon concentrations. Glucagon is a hormone that can encourage the liver to release stored glucose into the bloodstream.
Because its insulin-related action is glucose dependent, semaglutide behaves differently from directly injecting insulin. However, the risk of low blood glucose can increase when semaglutide is combined with insulin or certain other diabetes medicines, requiring professional monitoring and possible medication adjustment.
For suitable patients with type 2 diabetes, improved glucose regulation may contribute to reductions in fasting glucose, post-meal glucose and HbA1c.
4. Potential Cardiovascular Protection
The benefits associated with semaglutide may extend beyond changes in weight and blood glucose.
The SELECT cardiovascular outcomes trial investigated semaglutide in people who had overweight or obesity and established cardiovascular disease but did not have diabetes. Semaglutide reduced the incidence of a combined outcome consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke compared with placebo.
In May 2026, NICE recommended semaglutide as an option for reducing major adverse cardiovascular events in qualifying adults with established cardiovascular disease and a BMI of at least 27kg/m², alongside increased physical activity and a reduced-calorie diet.
This does not mean semaglutide replaces established cardiovascular treatments. Blood-pressure management, cholesterol treatment, smoking cessation, physical activity and other prescribed medicines may remain essential.
5. Improvements in Some Weight-Related Health Markers
Weight reduction can positively influence several measurements associated with metabolic health.
Clinical studies of semaglutide have reported improvements in areas such as waist circumference, blood pressure, blood-lipid measurements and markers of glucose regulation. The size of these changes varies according to the population studied, the formulation used, treatment duration and individual response.
Some benefits may be partly related to weight loss, while others could result from GLP-1 receptor activity itself. It would therefore be misleading to promise that every user will experience the same metabolic improvements.
6. Greater Mobility and Physical Function
For people living with obesity, weight reduction can sometimes make everyday movement and exercise more manageable.
A clinical trial involving participants with obesity and knee osteoarthritis found that semaglutide treatment, together with lifestyle counselling, resulted in greater weight reduction and improvements in osteoarthritis-related knee pain compared with placebo.
Semaglutide is not a direct treatment for every type of joint pain. However, reducing excess mechanical load may improve comfort and mobility for some people whose symptoms are affected by body weight.
7. Emerging Benefits for Liver Disease
Metabolic dysfunction-associated steatohepatitis, known as MASH, is a progressive liver condition involving fat accumulation, inflammation and liver scarring.
This development demonstrates how semaglutide research has expanded beyond weight management and diabetes. It should not, however, be interpreted as evidence that semaglutide is appropriate for every person with fatty liver disease.
Is Weight Loss Maintained After Semaglutide Is Stopped?
Semaglutide does not permanently remove the biological factors that can contribute to obesity.
In the extension of the STEP 1 trial, participants regained a substantial proportion of the weight they had lost after semaglutide was withdrawn. Several cardiometabolic improvements also began moving back towards their original levels.
This suggests obesity may require continuing management rather than a brief treatment followed by no further support.
Long-term nutrition, resistance training, physical activity, sleep quality and behavioural strategies remain important. Anyone considering stopping prescribed semaglutide should discuss an appropriate maintenance plan with their healthcare provider rather than stopping or changing treatment independently.
Does Semaglutide Only Reduce Body Fat?
Weight loss caused by a sustained calorie deficit usually includes a mixture of fat mass and lean tissue.
Semaglutide does not automatically preserve muscle. A person eating very little protein, remaining inactive or losing weight rapidly may also lose meaningful amounts of lean mass.
Where medically appropriate, a structured resistance-training programme, sufficient dietary protein and a sensible rate of weight reduction may help support muscle retention. These should be adapted to the person’s health, ability and clinical circumstances.
Common Side Effects
The most frequently reported adverse effects are gastrointestinal and can include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Headache
- Reduced appetite
These effects are often more noticeable when treatment begins or when the prescribed dose increases. Some people experience mild and temporary symptoms, while others find the adverse effects significant enough to stop treatment.
Persistent vomiting or diarrhoea may also increase the risk of dehydration. Anyone unable to keep fluids down should obtain medical advice.
Important Safety Considerations
Semaglutide is not appropriate for everyone, and a prescriber must consider medical history, current medication and individual risk factors.
GLP-1 medicines should not be used during pregnancy, while trying to become pregnant or while breastfeeding. Current UK guidance recommends stopping semaglutide at least two months before a planned pregnancy.
People should also tell their surgical and anaesthetic team that they use semaglutide before an operation or procedure involving sedation.
Final Thoughts
Semaglutide represents an important development in metabolic medicine.
Evidence supports potential benefits including:
- Reduced hunger and food cravings
- Improved feelings of fullness
- Clinically meaningful weight reduction
- Better blood-glucose control in type 2 diabetes
- Reduced cardiovascular risk in selected high-risk patients
- Potential improvements in mobility and weight-related health markers
- A developing role in treating MASH with liver fibrosis
These benefits must be balanced against side effects, individual suitability, the possibility of weight regain after treatment ends and the need for ongoing medical supervision.
Semaglutide should not be viewed as a casual fat-loss product or a substitute for nutrition, exercise and appropriate healthcare. When prescribed correctly to a suitable patient, however, it can form part of a broader evidence-based approach to managing obesity, type 2 diabetes and selected associated health risks.
Medical Disclaimer
This article is provided for general educational and informational purposes only. It does not constitute medical advice, diagnosis, prescribing guidance or instructions for using semaglutide.
Semaglutide is a prescription-only medicine in the United Kingdom. It should only be used when prescribed by an appropriately qualified healthcare professional following an individual medical assessment.
Do not begin, stop, increase, reduce or switch semaglutide products without consulting your doctor, pharmacist or prescribing clinician. Seek urgent medical attention if you experience severe persistent abdominal pain, sudden vision loss, significant dehydration or symptoms of a serious allergic reaction.